DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Medicine > Articles in academic journal >

Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.


File Description SizeFormat
CCP67_331.pdf124.31 kBAdobe PDFView/Open

Title: Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Authors: Yamaguchi, Hiroyuki / Soda, Hiroshi / Nakamura, Yoichi / Takasu, Mineyo / Tomonaga, Nanae / Nakano, Hirofumi / Doi, Seiji / Nakatomi, Katsumi / Nagashima, Seiji / Takatani, Hiroshi / Fukuda, Minoru / Hayashi, Tomayoshi / Tsukamoto, Kazuhiro / Kohno, Shigeru
Issue Date: Feb-2011
Publisher: Springer Berlin
Citation: Cancer Chemotherapy and Pharmacology, 67(2), pp.331-338; 2011
Abstract: PURPOSE: Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has dramatic effects in selective patients with non-small cell lung cancer (NSCLC). A simple non-invasive method for predicting the efficacy of gefitinib is preferable in clinical settings. In this study, we evaluated prospectively whether surfactant protein-A (SP-A) and -D (SP-D) may be new conventional predictors of the efficacy of gefitinib treatment. METHODS: We measured serum SP-A and SP-D levels on days 0 and 29 in 40 patients with advanced NSCLC treated with 250 mg gefitinib daily. Eligibility criteria included performance status </=3, age </=80 years, and stage IIIB-IV disease. In addition, EGFR mutations were analyzed in 24 patients. RESULTS: Multivariate analysis showed that favorable progression-free survival (PFS) after gefitinib treatment was associated with adenocarcinoma and high serum SP-D levels before treatment. EGFR mutation analysis of 24 patients showed that 16 patients had exon 19 deletion and/or exon 21 point mutations. EGFR mutations were significantly correlated with response to gefitinib and serum SP-D levels before treatment was significantly high in patients with the EGFR mutations. Serum SP-A levels were not associated with PFS. CONCLUSIONS: The present study showed that measurement of serum SP-D levels before treatment in patients with NSCLC may be a new surrogate marker for predicting the response to gefitinib.
Description: The original publication is available at www.springerlink.com
Keywords: Gefitinib / Non-small cell lung cancer / SP-A / SP-D
URI: http://hdl.handle.net/10069/23169
ISSN: 03445704
DOI: 10.1007/s00280-010-1325-x
PubMed ID: 20401612
Relational Links: http://hdl.handle.net/10069/26688
Rights: © Springer-Verlag 2010
Type: Journal Article
Text Version: author
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/23169

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace